The U.S. Food and Drug Administration (FDA) has approved AbbVie’s EMBLAVEO (aztreonam and avibactam) as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by susceptible Gram-negative microorganisms. Approval of this indication is ...